← All trials
NCT05132413
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 30, 2021
- Primary completion
- Dec 30, 2024
- Completion date
- Dec 30, 2024
- First posted
- Nov 24, 2021
- Last posted
- Nov 24, 2021
- Enrollment
- 561
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.